Exploring Urinary Proteomics for Early Detection of Cancer and Metabolic Diseases
A recent study published in PLOS One investigates the use of deep urine proteomics for the diagnosis of early-stage cancer, neurologic, and metabolic diseases. This research is significant as it explores a noninvasive and cost-effective method for disease detection through urinary biomarkers, which has been largely underutilized in proteomic studies that typically focus on single conditions. The study evaluated urinary protein signatures from samples collected by the Ukraine Association of Biobank (UAB), involving 264 participants: 198 patients diagnosed with various cancers and metabolic disorders, and 66 healthy controls. The conditions examined included kidney, bladder, melanoma, prostate, ovarian, endometrial, and cervical cancers, as well as multiple sclerosis and metabolic dysfunction-associated steatohepatitis.
Using the Olink Explore 3072 platform, the researchers conducted proteomic assays to identify disease-specific protein signatures. The primary outcome measured was the diagnostic accuracy of multiprotein urine panels compared to healthy controls, expressed as the area under the receiver operating characteristic curve (AUC). The study found that multiprotein models outperformed single protein assessments, with maximum AUCs ranging from 0.88 for multiple sclerosis to 0.98 for ovarian cancer, indicating high diagnostic potential.
The findings revealed three distinct expression patterns in the protein profiles: symmetric signals in melanoma and endometrial cancers, asymmetric patterns with many up-regulated proteins in cervical, ovarian, and prostate cancers, and broad up-regulation in kidney and bladder cancers as well as in metabolic dysfunction. Notably, some proteins demonstrated cross-disease importance, suggesting a shared biological basis among different conditions.
Despite these promising results, the authors caution that the exploratory nature of the study limits the conclusions that can be drawn. The reported accuracies should be viewed as upper-bound estimates that require further validation through prospective studies. Additionally, the complexities of urine sample collection and processing, along with the inherent variability in protein expression, pose challenges for the routine clinical application of these findings.
In conclusion, while the study underscores the potential of urinary proteomics for noninvasive diagnosis, it also highlights the need for continued research to refine these methods and validate their efficacy in broader clinical settings. The exploration of multi-protein panels could pave the way for more reliable diagnostic tools in the future, enhancing early detection capabilities for various diseases.




